JP2021533201A5 - - Google Patents

Info

Publication number
JP2021533201A5
JP2021533201A5 JP2021529491A JP2021529491A JP2021533201A5 JP 2021533201 A5 JP2021533201 A5 JP 2021533201A5 JP 2021529491 A JP2021529491 A JP 2021529491A JP 2021529491 A JP2021529491 A JP 2021529491A JP 2021533201 A5 JP2021533201 A5 JP 2021533201A5
Authority
JP
Japan
Prior art keywords
peg
tent
modified
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533201A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050793 external-priority patent/WO2020024002A1/en
Publication of JP2021533201A publication Critical patent/JP2021533201A/ja
Publication of JP2021533201A5 publication Critical patent/JP2021533201A5/ja
Priority to JP2023196375A priority Critical patent/JP7786745B2/ja
Priority to JP2025203043A priority patent/JP2026026159A/ja
Pending legal-status Critical Current

Links

JP2021529491A 2018-07-31 2019-07-30 Peg化破傷風神経毒素および筋緊張低下の治療 Pending JP2021533201A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023196375A JP7786745B2 (ja) 2018-07-31 2023-11-20 Peg化破傷風神経毒素および筋緊張低下の治療
JP2025203043A JP2026026159A (ja) 2018-07-31 2025-11-25 Peg化破傷風神経毒素および筋緊張低下の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902779 2018-07-31
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023196375A Division JP7786745B2 (ja) 2018-07-31 2023-11-20 Peg化破傷風神経毒素および筋緊張低下の治療

Publications (2)

Publication Number Publication Date
JP2021533201A JP2021533201A (ja) 2021-12-02
JP2021533201A5 true JP2021533201A5 (cg-RX-API-DMAC7.html) 2022-08-05

Family

ID=69230503

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021529491A Pending JP2021533201A (ja) 2018-07-31 2019-07-30 Peg化破傷風神経毒素および筋緊張低下の治療
JP2023196375A Active JP7786745B2 (ja) 2018-07-31 2023-11-20 Peg化破傷風神経毒素および筋緊張低下の治療
JP2025203043A Pending JP2026026159A (ja) 2018-07-31 2025-11-25 Peg化破傷風神経毒素および筋緊張低下の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023196375A Active JP7786745B2 (ja) 2018-07-31 2023-11-20 Peg化破傷風神経毒素および筋緊張低下の治療
JP2025203043A Pending JP2026026159A (ja) 2018-07-31 2025-11-25 Peg化破傷風神経毒素および筋緊張低下の治療

Country Status (11)

Country Link
US (1) US12697379B2 (cg-RX-API-DMAC7.html)
EP (2) EP4134133A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021533201A (cg-RX-API-DMAC7.html)
CN (2) CN112638937B (cg-RX-API-DMAC7.html)
AU (1) AU2019315327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001520A2 (cg-RX-API-DMAC7.html)
CA (2) CA3108079C (cg-RX-API-DMAC7.html)
MX (1) MX2021001181A (cg-RX-API-DMAC7.html)
NZ (1) NZ772266A (cg-RX-API-DMAC7.html)
SG (1) SG11202100646SA (cg-RX-API-DMAC7.html)
WO (1) WO2020024002A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4417131A1 (en) 2023-02-15 2024-08-21 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
GB9914861D0 (en) 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
MXPA03000014A (es) 2000-06-28 2004-09-13 Ira Sanders Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
US20040013687A1 (en) 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
WO2010124998A1 (en) * 2009-04-27 2010-11-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
WO2011115483A1 (en) 2010-03-15 2011-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptides, conjugates and method for increasing immunogenicity of a vaccine
EP3164149A1 (en) 2014-07-02 2017-05-10 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
MX2018002183A (es) * 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
WO2019118974A2 (en) * 2017-12-15 2019-06-20 The Medical College Of Wisconsin, Inc. Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms
WO2021155427A1 (en) * 2020-02-03 2021-08-12 Snoretox Pty Ltd Composition and method

Similar Documents

Publication Publication Date Title
RU2471867C2 (ru) Гиалуронидаза и способ ее применения
JP7439367B2 (ja) 最適化化合物
JP2023081969A (ja) Tlrアゴニストによる呼吸器感染症の治療
JP2005523946A5 (cg-RX-API-DMAC7.html)
RU2018138195A (ru) Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
JP2003507438A5 (cg-RX-API-DMAC7.html)
JP2020512363A5 (cg-RX-API-DMAC7.html)
JP4234439B2 (ja) Il−12発現調節剤
RU2010144014A (ru) Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
JP2026067913A (ja) 新規なペプチドと多糖類とのコンジュゲート
JP2016537432A5 (cg-RX-API-DMAC7.html)
CA3160114A1 (en) New multi-functional oligopeptides
US20210177795A1 (en) Administering compounds
CN120731082A (zh) 新多功能寡肽
JP2023521623A (ja) 過炎症性症候群の処置
JP2024511369A (ja) 新規のペプチドコンジュゲート
JP2008500277A5 (cg-RX-API-DMAC7.html)
CN116568309B (zh) 一种用于预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒
JP2009542609A5 (cg-RX-API-DMAC7.html)
WO2024192149A3 (en) Method of treating enterovirus in chronic obstructive pulmonary disease patients
JP6559898B2 (ja) スクアレンを含む両親媒性ポリアミノ酸高分子に基づくワクチンの免疫補助剤組成物
RU2019134182A (ru) Новые способы лечения рассеянного склероза
JP2004529158A5 (cg-RX-API-DMAC7.html)
JPWO2020255574A5 (cg-RX-API-DMAC7.html)
US20210087232A1 (en) D-enantiomeric peptides for anti-inflammatory treatment of amyotropic lateral sclerosis (als) and other diseases driven by neuro-inflammation